Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.19.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Cash Flows from Operating Activities:    
Net loss $ (452,103) $ (267,276)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 9,024 111,899
Amortization of debt discounts
Amortization of patent and web design costs
Research and development - license acquired
Stock-based compensation expenses 59,171
Loss on change in fair value of derivatives (86,403) (69,620)
Changes in operating assets and liabilities:    
Accounts receivable
Prepaid Expenses
Furniture and Equipment (136,142)
Accounts payable 327,302 100,937
Accrued payroll and benefits
Due to related party 20,610 17,762
Accrued liabilities 19,794 76,746
Net cash used in operating activities (297,919) 29,619
Cash Flows from Investing Activities:    
Cash acquired with acquisition of Theranostics Health, Inc. assets
Licensing costs 56,000
Other Assets 13,800 20,000
Website development costs
Net cash provided by (used in) investing activities 69,800 20,000
Cash Flows from Financing Activities:    
Proceeds from the issuance of Preferred Stock 259,470
Net cash provided by financing activities 259,470
Net increase in cash 31,352 49,619
Cash at beginning of period 30,896 1,348
Cash at end of period 62,248 50,967
Supplemental disclosure of noncash investing and financing activities:    
Shares issued in settlement of related party debt
Reclass derivative liability to equity upon note payment
Common stock issued to acquire net assets of Theranostics Health, Inc.
Common stock issued to acquire net assets of Amarantus Diagnostics, Inc.